, Tracking Stock Market Picks
Enter Symbol:
Sciclone Pharmaceuticals, Inc. (SCLN) [hlAlert]

up 248.87 %

Sciclone Pharmaceuticals, Inc. (SCLN) rated Buy with price target $5 by ThinkEquity

Posted on: Wednesday,  Jun 3, 2009  8:25 AM ET by ThinkEquity

ThinkEquity rated Buy Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) on 06/03/2009, when the stock price was $2.23. Since
then, Sciclone Pharmaceuticals, Inc. has gained 248.88% as of 01/05/2016's recent price of $7.78.
If you would have followed this ThinkEquity's recommendation on SCLN, you would have gained 248.87% of your investment in 2407 days.

Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/3/2009 8:25 AM Buy
2.23 5.00
as of 12/31/2009
1 Week up  62.65 %
1 Month up  83.17 %
3 Months down  -7.76 %
1 YTD up  75.78 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy